Buy Abiraterone (154229-19-3) hplc≥98% | AASraw suppliers
AASraw produces Cannabidiol(CBD) powder and Hemp Essential Oil in bulk!

Abiraterone (154229-19-3)

Rating: SKU: 154229-19-3. Category:

AASraw is with synthesis and production ability from gram to mass order of Abiraterone (154229-19-3), under CGMP regulation and trackable quality control system.

Product Description


Abiraterone (154229-19-3) video




Abiraterone (154229-19-3) Specification:

Chemical Structure: Product Name: Abiraterone
Buy Abiraterone (154229-19-3) hplc≥98% | AASraw suppliers Cas No.: 154229-19-3
Molecular Formula: C24H31NO
Molecular Weight: 349.5
Synonyms: Abiraterone



CB 7598


Storage: Dry, dark
Documents(COA & HPLC etc.): Available


Abiraterone (154229-19-3) Description:

Abiraterone powder, also known as CB7598, is the active metabolite of abiraterone acetate, which is an orally active acetate ester of the steroidal compound abiraterone with antiandrogen activity, used to treat metastatic, castration-resistant prostate cancer.

Administered as the O-acetate, it is used for treatment of metastatic castrate-resistant prostate cancer. It has a role as an antineoplastic agent and an EC (steroid 17alpha-monooxygenase) inhibitor. It is a 3beta-sterol and a member of pyridines. It derives from a hydride of an androstane.



  • 1: Grist E, Attard G. The development of abiraterone acetate for castration-resistant prostate cancer. Urol Oncol. 2015 Jun;33(6):289-294. doi: 10.1016/j.urolonc.2015.03.021. Review. PubMed PMID: 26025264.
  • 2: Petrelli F, Coinu A, Borgonovo K, Cabiddu M, Ghilardi M, Lonati V, Barni S. Enzalutamide After Docetaxel and Abiraterone Acetate Treatment in Prostate Cancer: A Pooled Analysis of 10 Case Series. Clin Genitourin Cancer. 2015 Jun;13(3):193-198. doi: 10.1016/j.clgc.2014.10.006. Epub 2014 Nov 7. Review. PubMed PMID: 25466676.
  • 3: Giacinti S, Bassanelli M, Aschelter AM, Milano A, Roberto M, Marchetti P. Resistance to abiraterone in castration-resistant prostate cancer: a review of the literature. Anticancer Res. 2014 Nov;34(11):6265-9. Review. PubMed PMID: 25368223.
  • 4: Zobniw CM, Causebrook A, Fong MK. Clinical use of abiraterone in the treatment of metastatic castration-resistant prostate cancer. Res Rep Urol. 2014 Aug 5;6:97-105. doi: 10.2147/RRU.S29003. eCollection 2014. Review. PubMed PMID: 25157341; PubMed Central PMCID: PMC4128838.
  • 5: Francini E, Petrioli R, Roviello G. No clear evidence of a clinical benefit of a sequential therapy regimen with abiraterone acetate and enzalutamide. Expert Rev Anticancer Ther. 2014 Oct;14(10):1135-40. doi: 10.1586/14737140.2014.949677. Epub 2014 Aug 19. Review. PubMed PMID: 25135334.